MeridianLink announced an underwritten secondary public offering of 6 million shares by funds managed by Thoma Bravo. The selling stockholders plan to grant the underwriter an option to purchase up to ...
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials ...